Simple at-home brainwave test could detect Alzheimer’s years before diagnosis
According to a new study, a new three -minute “brainwave” test can detect Alzheimer’s years ago before the diagnosis.
Researchers at the University of Bath believe that existing means of diagnostic means “Alzheimer’s first 10 to 20 years”, but a new “Fastball” test can change the way of detecting the disease.
The 180-second “passive” test, which records the electrical activity in the brain while the participants saw an image flow, has been found to rely on memory problems in people with mild cognitive disorder (MCI).
For the first time, the researchers showed that the test could take place in patients’ homes, GP surgeries and memory clinics, and said that researchers could be the key to touching a “emergency” need for lower costly and more accessible scanning.
He added that Yeni Alzheimer’s “miracle” drugs mean that the breakthrough of Hardemab and Lacemab means “more important than ever”.
Hardemab and Laceemab are the targeted antibody drugs that connect to Amyiloid, a protein accumulated in the brains of people living with Alzheimer’s disease. Currently, drugs that are not available in NHS have been proven to be the most effective in Alzheimer’s early stages.
The researchers described Fastball as a passive EEG (electroencephalogram) test using sensors placed on the scalp to monitor the automatic responses of the brain without asking the participants to follow or recall the instructions. They said that it made the test more accessible and objective than traditional memory tests.
In addition to fastball test, patients in the experiment have completed a number of neuropsychological memory assessments, continuous attention and general cognitive function.
Researchers found that Amnestic MCI showed significant decreased response to fastball test compared to significant memory loss such as forgetting the symptoms, appointments and recent speeches.
The group of researchers re-tested a year later, and found that Fastball shows “mid to medium to good test-testing reliability in healthy elderly adults.
The study is a cognitive neuroscientist at the Department of Psychology of Bath. It was ruled by George Stothart. He said: “There is an urgent need for the right, practical tools to identify Alzheimer’s scale. Fastball works in cheap, portable and real world environments.”
It was financed by the Academy of Medical Sciences and dementia research was supported by Brace. CEO Chris Williams described Fastball as a “incredible tool ve and said that the team was looking forward to seeing what can develop in the future.
“Fastball is an incredible tool that can present to anyone who cannot reach the diagnosis of dementia in the clinical environment for any reason,” he said. “Brace has been supporting Fastball’s development for several years and we are excited to see what Dr Stothart’s team will achieve with the continuous support of the charity in the next few years.”
The Alzheimer’s Association estimates that there are about 982,000 people in the UK, but there is no diagnosis of more than one third. The number is expected to rise to 1.4 million by 2040.
